4/4
10:09 am
spro
Spero Therapeutics, Inc. (NASDAQ: SPRO) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald.
Medium
Report
Spero Therapeutics, Inc. (NASDAQ: SPRO) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald.
4/4
09:44 am
spro
Rating for SPRO
Medium
Report
Rating for SPRO
3/18
02:52 pm
spro
Spero Therapeutics, Inc. (NASDAQ: SPRO) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $7.00 price target on the stock.
Low
Report
Spero Therapeutics, Inc. (NASDAQ: SPRO) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $7.00 price target on the stock.